Delving into the Latest Updates on Affectis Pharmaceuticals AG with Synapse

Overview

Basic Info

Introduction

Affectis Pharmaceuticals AG is a company that specializes in creating medications for the treatment of neurodegenerative and neuroinflammatory diseases. Their current pipeline includes products such as AFC-5128, P2X7 Compounds, AFC-5278, and AFC-08. The company was established in 2004 by Florian Holsboer, Wolfgang Wurst, and Herbert Stadler and is based in Dortmund, Germany.

This multicenter study aims to investigate the safety and efficacy of cimicoxib, a selective COX-2 inhibitor, in combination with sertraline compared to sertraline combined with placebo in patients with major depression. This clinical study is based on the assumption that adjunctive treatment of major depression with a COX-2 inhibitor may be beneficial.

Start Date01 Oct 2007

Sponsor / Collaborator

Affectis Pharmaceuticals AG

[+1]

100 Clinical Results associated with Affectis Pharmaceuticals AG

Login to view more data

0 Patents (Medical) associated with Affectis Pharmaceuticals AG

Login to view more data

12

Literatures (Medical) associated with Affectis Pharmaceuticals AG

01 Jun 2024·Purinergic Signalling

Functional expression of the ATP-gated P2X7 receptor in human iPSC-derived astrocytes

Article

Author: de Diego-Garcia, Laura ; Hamacher, Michael ; Engel, Tobias ; Alves, Mariana ; Kesavan, Jaideep ; Méndez, Aida Menéndez ; Prehn, Jochen H M ; Henshall, David C ; Watters, Orla ; Dinkel, Klaus

AbstractActivation of the ATP-gated P2X7 receptor (P2X7R), implicated in numerous diseases of the brain, can trigger diverse responses such as the release of pro-inflammatory cytokines, modulation of neurotransmission, cell proliferation or cell death. However, despite the known species-specific differences in its pharmacological properties, to date, most functional studies on P2X7R responses have been analyzed in cells from rodents or immortalised cell lines. To assess the endogenous and functional expression of P2X7Rs in human astrocytes, we differentiated human-induced pluripotent stem cells (hiPSCs) into GFAP and S100 β-expressing astrocytes. Immunostaining revealed prominent punctate P2X7R staining. P2X7R protein expression was also confirmed by Western blot. Importantly, stimulation with the potent non-selective P2X7R agonist 2′,3′-O-(benzoyl-4-benzoyl)-adenosine 5′- triphosphate (BzATP) or endogenous agonist ATP induced robust calcium rises in hiPSC-derived astrocytes which were blocked by the selective P2X7R antagonists AFC-5128 or JNJ-47965567. Our findings provide evidence for the functional expression of P2X7Rs in hiPSC-derived astrocytes and support their in vitro utility in investigating the role of the P2X7R and drug screening in disorders of the central nervous system (CNS).

01 Feb 2019·European Journal of PharmacologyQ3 · MEDICINE

Chronic high dose P2X7 receptor inhibition exacerbates cancer-induced bone pain

Q3 · MEDICINE

Article

Author: Appel, Camilla Kristine ; Bennedbæk, Heidi Bahrt ; Al-Dihaissy, Tamara ; Falk, Sarah ; Heegaard, Anne-Marie ; Unger, Anke ; Dinkel, Klaus

The functional role of P2X7 receptor (P2X7R) inhibition in cancer-induced bone pain has been highly contradictory. Whereas knockout studies have suggested pro-nociceptive effects, pharmacological studies suggest anti-nociceptive or no effect. The discrepancy is likely linked to the highly polymorphic nature of the P2X7R and the related functional differences in different tissue and conditions. In this study we tested the analgesic potential of AFC5261, a selective P2X7R antagonist, in a rat model of cancer-induced bone pain to evaluate if the opposing pro- and anti-nociceptive effects could be a consequence of long vs. short term inhibition of the P2X7R. Following intratibial inoculation of MRMT-1 carcinoma cells, movement-evoked and background pain was assessed with the limb use and weight-bearing test, and the effect of acute and chronic AFC5261-treatement evaluated. Bone degradation and tumor progression was in addition evaluated with x-ray densitometry and bioluminescence, respectively. In an acute treatment regime, a single administration of 300 mg/kg AFC5261 had no effect on either weight-bearing or limb use deficits. In contrast, morphine significantly increased both the limb use and weight-bearing ratio. In a chronic treatment study, BID administration of 300 mg/kg AFC5261 exacerbated the pain-related behavior, demonstrated by an earlier onset of both limb use and weight-bearing deficits without affecting the overall bone degradation or tumor progression. In contrast, 50 mg/kg and 100 mg/kg AFC5261 had no effect on the pain-related behavior. Overall, the data suggest that whereas acute P2X7R inhibition has no effect on the pain-related behavior, chronic inhibition exacerbate the cancer-induced bone pain.

30 Sep 2011·ScienceQ1 · CROSS-FIELD

Glutamatergic and Dopaminergic Neurons Mediate Anxiogenic and Anxiolytic Effects of CRHR1

Q1 · CROSS-FIELD

Article

Author: Sillaber, Inge ; Holsboer, Florian ; Engblom, David ; Touma, Chadi ; Schweizer, Martin ; Schütz, Günther ; Wotjak, Carsten T. ; Vogl, Annette M. ; Thoeringer, Christoph ; Deussing, Jan M. ; Ehrenberg, Stefanie ; Avrabos, Charilaos ; Refojo, Damian ; Eder, Matthias ; Dedic, Nina ; Schumacher, Marion ; Kuehne, Claudia ; Wurst, Wolfgang ; von Wolff, Gregor ; Nave, Klaus-Armin

An imbalance between CRHR1-controlled anxiogenic glutamatergic and anxiolytic dopaminergic systems might lead to emotional disturbances.

100 Deals associated with Affectis Pharmaceuticals AG

Login to view more data

100 Translational Medicine associated with Affectis Pharmaceuticals AG

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AFC-08 ( Purinergic P2 receptor x TMEFF2 )	Depressive Disorder More	Pending
Cimicoxib ( COX-2 )	Depressive Disorder, Major More	Pending
AFC-5278 ( P2X7 receptor )	Osteoporosis More	Pending
AF-4025 ( P2X7 receptor )	Depressive Disorder More	Pending
AFC-5128 ( P2X7 receptor )	Multiple Sclerosis More	Pending